Moneycontrol
Nov 11, 2016 12:43 PM IST | Source: CNBC-TV18

Targetting Rs 300 cr revenue by FY17: Mangalam Drugs

Speaking to CNBC-TV18 Govardhan Dhoot, MD, Mangalam Drugs, said that margins have improved. Revenue growth is on track and it is looking at Rs 300 crore of revenue by end of FY17. We are Hoping for a 10-15 percent growth, he said. “We are focussing on the topline.”


Speaking to CNBC-TV18 Govardhan Dhoot, MD, Mangalam Drugs, said that margins have improved. Revenue growth is on track and it is looking at Rs 300 crore of revenue by end of FY17. We are Hoping for a 10-15 percent growth, he said. “We are focussing on the topline.”

"We are in sync with revenue because of better yields bad realisations and strong purchasing power."

Watch video for more...

X
Sections
Follow us on
Available On